CellChorus vs Epic Systems
Side-by-side comparison of AI visibility scores, market position, and capabilities
Houston biotech with visual AI TIMING platform analyzing individual cell behaviors in nanowell grids; $5.78M raised plus NIH STTR grant targeting CAR-T quality release and drug discovery screening.
About
CellChorus is a Houston-based biotechnology company developing the TIMING (Time-lapse Imaging Microscopy in Nanowell Grids) platform — a visual AI system that analyzes individual cell behaviors over time in nanoscale grid arrays to characterize how cells interact, move, and function, enabling drug developers and cell therapy manufacturers to optimize their biologics and cell therapies with unprecedented single-cell resolution. Founded in 2021 and backed with $5.78 million in equity funding plus $3.4 million in non-dilutive grants including a $2.5 million NIH STTR Fast-Track grant in partnership with University of Houston, CellChorus serves biotech researchers, cell therapy manufacturers, and pharmaceutical companies.
Epic holds over 42% of U.S. acute care hospital EHR market share and is embedding AI across 150+ clinical workflows for 2026, while facing antitrust scrutiny.
About
Epic Systems Corporation was founded in 1979 by Judith Faulkner and is headquartered in Verona, Wisconsin, remaining privately held with Faulkner as majority owner. The company develops large-scale electronic health record systems and reports that more than 305 million patients have a record in Epic, covering the majority of U.S. academic medical centers and large health systems including Kaiser Permanente, Mayo Clinic, Johns Hopkins, and Cleveland Clinic. Epic commands approximately 42% of U.S. acute care hospitals and nearly 55% of acute care hospital beds, making it the undisputed market leader in enterprise EHR.
AI Visibility Head-to-Head
Key Details
Capabilities & Ecosystem
Capabilities
Integrations
Also Compare
Track AI Visibility in Real Time
Monitor how your brand performs across ChatGPT, Gemini, Perplexity, Claude, and Grok daily.